{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-017984","form_type":"8-K","ticker":"RMTI","cik":"0001041024","company_name":"ROCKWELL MEDICAL, INC.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.730561+00:00","generated_at":"2026-06-15T00:29:03.968396+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rockwell Medical Q1 revenue $19.7M (+22.4% YoY); net loss narrows to $0.10/share","bullets":["Revenue of $19.7M, up 22.4% YoY; gross profit of $2.6M vs gross loss of $0.8M in Q1 2022.","Net loss of $1.75M ($0.10/share) vs $7.2M ($0.84) a year ago; operating loss improved to $1.4M.","Reiterates 2023 guidance: revenue $78-82M, gross profit $7-9M, targeting profitability in 2024.","Signed long-term supply agreements with largest U.S. non-profit dialysis provider and Concerto Renal Services.","Assumed full commercial responsibility for Baxter customers; cash stood at $16.8M at quarter-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-017984","json":"https://secwatch.observer/filing/0001628280-23-017984.json","markdown":"https://secwatch.observer/filing/0001628280-23-017984.md","text":"https://secwatch.observer/filing/0001628280-23-017984.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1041024/000162828023017984/0001628280-23-017984-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1041024/000162828023017984/rmti-20230515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T00:29:03.968396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e2965bd9aa52e9e3820734fe098b7102675541e6","claim":"ROCKWELL MEDICAL, INC. reported the three months ended March 31, 2023 results: revenue $19.7 million, net income $1.75 million, EPS $0.10* per share. Guidance reaffirmed.","evidence_excerpt":"in such a filing. --- EX-99.1 (EX-99.1) --- Rockwell Medical Announces First Quarter 2023 Results • Achieved fourth consecutive quarter of revenue growth with new high of $19.7 million, representing a 22.4% increase over the same period in 2022 • Achieved $2.6 million in gross profit, representing a 425% increase over the same period in 2022 • Continued to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1041024/000162828023017984/0001628280-23-017984-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Revenue","value":"$19.7 million"},{"label":"Net income","value":"$1.75 million"},{"label":"EPS","value":"$0.10* per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}